Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that two scientific abstracts with clinical data from the SPARKLE Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback